|
Gene: EMILIN1 |
Gene summary for EMILIN1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | EMILIN1 | Gene ID | 11117 |
Gene name | elastin microfibril interfacer 1 | |
Gene Alias | EMI | |
Cytomap | 2p23.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9Y6C2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11117 | EMILIN1 | AEH-subject1 | Human | Endometrium | AEH | 7.92e-24 | -4.80e-01 | -0.3059 |
11117 | EMILIN1 | AEH-subject2 | Human | Endometrium | AEH | 5.67e-27 | -4.94e-01 | -0.2525 |
11117 | EMILIN1 | AEH-subject3 | Human | Endometrium | AEH | 6.19e-21 | -4.66e-01 | -0.2576 |
11117 | EMILIN1 | AEH-subject4 | Human | Endometrium | AEH | 3.20e-10 | -3.86e-01 | -0.2657 |
11117 | EMILIN1 | AEH-subject5 | Human | Endometrium | AEH | 3.14e-30 | -5.00e-01 | -0.2953 |
11117 | EMILIN1 | EEC-subject1 | Human | Endometrium | EEC | 3.93e-21 | -4.90e-01 | -0.2682 |
11117 | EMILIN1 | EEC-subject2 | Human | Endometrium | EEC | 8.22e-27 | -4.98e-01 | -0.2607 |
11117 | EMILIN1 | EEC-subject3 | Human | Endometrium | EEC | 2.32e-33 | -4.88e-01 | -0.2525 |
11117 | EMILIN1 | EEC-subject4 | Human | Endometrium | EEC | 1.98e-27 | -4.80e-01 | -0.2571 |
11117 | EMILIN1 | EEC-subject5 | Human | Endometrium | EEC | 3.42e-26 | -4.98e-01 | -0.249 |
11117 | EMILIN1 | GSM5276935 | Human | Endometrium | EEC | 5.05e-31 | -4.94e-01 | -0.123 |
11117 | EMILIN1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.19e-24 | -5.02e-01 | -0.1869 |
11117 | EMILIN1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 5.85e-22 | -5.02e-01 | -0.1875 |
11117 | EMILIN1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.62e-25 | -5.02e-01 | -0.1883 |
11117 | EMILIN1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 4.41e-32 | -4.95e-01 | -0.1934 |
11117 | EMILIN1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.26e-30 | -5.02e-01 | -0.1917 |
11117 | EMILIN1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 3.17e-31 | -4.89e-01 | -0.1916 |
11117 | EMILIN1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 4.91e-19 | -4.56e-01 | -0.1269 |
11117 | EMILIN1 | P2T-E | Human | Esophagus | ESCC | 1.84e-54 | 1.02e+00 | 0.1177 |
11117 | EMILIN1 | P4T-E | Human | Esophagus | ESCC | 2.81e-07 | 3.71e-01 | 0.1323 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001081015 | Endometrium | AEH | regulation of cell-substrate adhesion | 64/2100 | 221/18723 | 3.85e-13 | 9.62e-11 | 64 |
GO:00315899 | Endometrium | AEH | cell-substrate adhesion | 87/2100 | 363/18723 | 3.51e-12 | 5.70e-10 | 87 |
GO:004578516 | Endometrium | AEH | positive regulation of cell adhesion | 96/2100 | 437/18723 | 5.50e-11 | 7.18e-09 | 96 |
GO:190290316 | Endometrium | AEH | regulation of supramolecular fiber organization | 83/2100 | 383/18723 | 2.20e-09 | 1.78e-07 | 83 |
GO:001081116 | Endometrium | AEH | positive regulation of cell-substrate adhesion | 38/2100 | 123/18723 | 3.08e-09 | 2.26e-07 | 38 |
GO:00071609 | Endometrium | AEH | cell-matrix adhesion | 54/2100 | 233/18723 | 1.42e-07 | 6.37e-06 | 54 |
GO:19029049 | Endometrium | AEH | negative regulation of supramolecular fiber organization | 39/2100 | 167/18723 | 6.07e-06 | 1.50e-04 | 39 |
GO:00715596 | Endometrium | AEH | response to transforming growth factor beta | 53/2100 | 256/18723 | 7.01e-06 | 1.69e-04 | 53 |
GO:00071787 | Endometrium | AEH | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2100 | 355/18723 | 1.28e-05 | 2.80e-04 | 67 |
GO:00715606 | Endometrium | AEH | cellular response to transforming growth factor beta stimulus | 51/2100 | 250/18723 | 1.59e-05 | 3.32e-04 | 51 |
GO:00303364 | Endometrium | AEH | negative regulation of cell migration | 65/2100 | 344/18723 | 1.65e-05 | 3.42e-04 | 65 |
GO:20001464 | Endometrium | AEH | negative regulation of cell motility | 67/2100 | 359/18723 | 1.86e-05 | 3.77e-04 | 67 |
GO:00512714 | Endometrium | AEH | negative regulation of cellular component movement | 68/2100 | 367/18723 | 2.06e-05 | 4.11e-04 | 68 |
GO:00400134 | Endometrium | AEH | negative regulation of locomotion | 70/2100 | 391/18723 | 4.95e-05 | 8.05e-04 | 70 |
GO:004593616 | Endometrium | AEH | negative regulation of phosphate metabolic process | 77/2100 | 441/18723 | 5.13e-05 | 8.25e-04 | 77 |
GO:001056316 | Endometrium | AEH | negative regulation of phosphorus metabolic process | 77/2100 | 442/18723 | 5.54e-05 | 8.79e-04 | 77 |
GO:00509008 | Endometrium | AEH | leukocyte migration | 64/2100 | 369/18723 | 2.57e-04 | 3.04e-03 | 64 |
GO:000193315 | Endometrium | AEH | negative regulation of protein phosphorylation | 60/2100 | 342/18723 | 2.89e-04 | 3.31e-03 | 60 |
GO:004232615 | Endometrium | AEH | negative regulation of phosphorylation | 65/2100 | 385/18723 | 4.93e-04 | 5.06e-03 | 65 |
GO:00071796 | Endometrium | AEH | transforming growth factor beta receptor signaling pathway | 38/2100 | 198/18723 | 6.41e-04 | 6.23e-03 | 38 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EMILIN1 | SNV | Missense_Mutation | rs140139205 | c.299N>A | p.Arg100His | p.R100H | protein_coding | deleterious(0) | benign(0.147) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
EMILIN1 | SNV | Missense_Mutation | novel | c.2015N>A | p.Gly672Asp | p.G672D | protein_coding | tolerated(0.38) | benign(0.32) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
EMILIN1 | SNV | Missense_Mutation | novel | c.50N>A | p.Ala17Glu | p.A17E | protein_coding | tolerated(0.93) | benign(0.127) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
EMILIN1 | SNV | Missense_Mutation | c.1879N>A | p.Asp627Asn | p.D627N | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-38-4629-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
EMILIN1 | SNV | Missense_Mutation | c.135N>T | p.Gln45His | p.Q45H | protein_coding | deleterious(0.01) | probably_damaging(0.919) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | ||
EMILIN1 | SNV | Missense_Mutation | c.136N>T | p.Ala46Ser | p.A46S | protein_coding | tolerated(0.09) | benign(0.236) | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | ||
EMILIN1 | SNV | Missense_Mutation | c.348N>A | p.Met116Ile | p.M116I | protein_coding | deleterious(0.01) | possibly_damaging(0.661) | TCGA-49-AAR9-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
EMILIN1 | SNV | Missense_Mutation | c.2296N>T | p.Asn766Tyr | p.N766Y | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-49-AARQ-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
EMILIN1 | SNV | Missense_Mutation | c.1663G>C | p.Glu555Gln | p.E555Q | protein_coding | tolerated(0.17) | possibly_damaging(0.629) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
EMILIN1 | SNV | Missense_Mutation | rs774000688 | c.1634N>A | p.Arg545His | p.R545H | protein_coding | tolerated(0.13) | benign(0.019) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |